Moreover, the enhanced anti-myeloma effects were also validated in XG-2 DNMT3B KD cells (Figure S10B) and in the murine 5T33MM model (Fig. 7E), for which the primary tumor cells (5T33MMvv) were again found much more sensitive to NA treatment than the BMSC (Figure S11A-C). Here, DNMT3B is linked to plasma cell myeloma.